Skip Ribbon Commands
Skip to main content
Dr. Saima Zafar
Associate Professor
DEPARTMENT OF BIOMEDICAL ENGINEERING & SCIENCES

SMME
National University of Sciences and Technology (NUST)
H-12, NUST HQ, Islamabad.
Tel : +925190856057

Specialization
Molecular Neuroscience (Proteomics, Diagnostics and therapeutics/Translational medicine)

Education
PhD Molecular Neuroscience Georg-August-Universität Göttingen, Germany

Dr. Saima Zafar accomplished PhD fellowship and Research scientist position, 6th framework European Union (EU)-funded project, “Identification of potential biomarkers of CJD using STrEPTM technology and proteomics” and received her Ph.D. Molecular biology Degree in Jan., 2011 from, Department of Clinical Chemistry, Internal Medicine, University Medical Center Göttingen, Georg-August-University Göttingen, Germany.  She attained Post-Doctoral fellowship in 2011, Deutschen Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL)-funded project, “Kidney fibrosis and Mycophenolic acid”. Advanced, she established research projects in the Clinical Dementia Center, Department of Neurology, for the protection of the food chain from prions (Priority) European Union (EU) funded projects to evaluate the epidemiology and surveillance of CJD subtypes.

She served as the Head of the Proteomics and interact-omics unit in the prion research group at Dept. of Neurology, Göttingen from 2012 till January 2019. She established four labs in neurology Department, Georg-August University, University Medical Center Goettingen (UMG), Goettingen, Germany. The lab specialties are below,

  • Diagnostic lab for neurological diseases,

  • Proteomics and interactomics lab

  • Translational therapeutic lab and

  • Infectious lab S3 for contagious brain diseases

Dr. Saima Zafar joined (Jan., 2019) biomedical science, SMME, NUST. Her impending research plans are to build on the foundations of new laboratories, center and skilled scientists and to further develop early neurological disease biomarkers and detection of therapeutic targets, in collaboration with other disciplines such as neurosurgery, neuroscience, biomedical science and in addition to the medical industry to expedite and enhance new discoveries and their meaningful translation from “bench to bedside.”

Professional Training

  • RNAseq data analysis using galaxy,  Medical Biometry and statistical, Bioinformatics Transcriptome and Genome Analysis Laboratory TAL UMG Göttingen Germany.

  • RNAseq data analysis, RNAseq data analysis, Certificate, Neurology Zentrum Informatik, Statistik und Epidemiologie, Institut für Medizinische Statistik.

  • Tonsil Biopsy meeting, Human/animal Tonsil Biopsy Training, Infectious study University of Edinburgh, Edinburgh, Scotland, 30-31st January 2013

  • Light sheet microscopy hand on experience-Light sheet microscopy hand on experience Neurology, Georg-August-University, GZMB-Göttingen, Germany

  • Advances in Bioanalytical Mass Spectrometry, Advances in Bioanalytical Mass Spectrometry Clinical Chemistry, Max-Planck-Institute for Experimental Medicine Göttingen, Germany

  • Stem Cell –Tumor-Proteomics, Stem Cell –Tumor-Proteomics Proteomics Hamburg February



​​​

  • The main research interests include Genomics leading to Proteomics and interactomics based techniques within deeper understanding of molecular mechanisms and post-translational modifications by regulating the function and translocation of proteins involved in Alzheimer’s, Parkinson’s, degenerative dementia, Creutzfeldt–Jakob disease (CJD) diseases. The main projects are,

  • Current she is working on high impacted projects to in Pakistan, few are as below,

  • Development of an in vitro amplification assay for misfolded proteins in neurodegenerative diseases. We are developing in-vitro protein amplification systems for the detection of misfolded proteins in human cerebrospinal fluid and blood of human neurodegenerative diseases.

  • Proteomics/METABOLOMICS lab for translational medicine and therapeutics

  • We are establishing proteomics based analysis to ascertain the main risk modifiers and disease signatures, to better understand the underlying disease mechanisms contributing to the neurodegenerative process. Classical gel based and new in-solution SWATH based techniques will be applied to separate identifies protein complexes from different fractions (including soluble fraction and non-soluble fractions) and identified by ESI-Q-TOF mass spectrometry.

  • Establishment and commercialization of Blood-Based Early Diagnostic assay/KIT for Alzheimer’s disease.

  • Establishment of an in-vitro diagnostics biomarker products for diagnosis of early Alzheimer’s cases and developed a blood-based ELISA technique for analyzing mid-domain amyloid beta peptides (a widely studied plasma biomarker for Alzheimer’s) in macrophages. Commercialization of a blood macrophage-based immunoassay to detect Alzheimer’s in Pakistan at cost effective manner and export of the blood macrophage-based immunoassay kit worldwide will generate revenue.

  • Digital-biomarkers for early diagnosis

  • We are establishing the Emergence and implementation of digital-biomarkers for early diagnosis of Alzheimer’s disease and other dementia utilizing biomedical devices and in long term after the successful implementation of the project, we will be able to provide longitudinal disease-related digital biomarkers to a healthcare practitioner, to allow for objective and continuous clinical evaluation of a user.

  • Vascular dementia

  • We are establishing and try to uncover the therapeutic strategy for vascular dementia leading to stroke in Pakistani population.

  • Early Diagnostics for Neurodegenerative diseases

  • Dr. Saima’s utmost aspiration is to establish the lab for early diagnosis of Alzheimer’s and Parkinson patients of Pakistan so they can deal with the disease. She is establishing the international standard test and is in trial phase.

  • The current Impact factor of Dr. Saima Zafar is 255.097, she published and contributed in more than 80 high impact publications many books, chapter and international conferences.

  • Year 2050, Pakistan will become the third most populous country of the world with an estimated population of 380 million, leaving behind United States and Dr. Saima Zafar is working to lower the impression of that big concern.

  • Dr. Saima Zafar won 6 big European and Canadian Research Grants between the year 2012 AND 2018 and established above mentioned labs.

2016 – 2018              Physics-to Medicine initiative grant. Germany (90000 € )

2013 - 2018               APRI- Germany –Canada(187500 € )

2013 - 2017               Helmholtz-Alberta Initiative-Infectious Diseases Research Germany -Canada 50915 € )

2013                          Equipment grant for High-resolution Spectral Confocal TCS SPE,JPND. Germany(155536€ )

2012-2014                 BMBF Germany (560712 € )

2012-2014                 JPND. Europe –Germany (226800 € ) 

Current Impact factor :  255.097 

Citations:   668

h-index: 16

i10-index: 23

Total publication

Please visit for updates

  • https://scholar.google.com/citations?hl=en&user=ghiReEwAAAAJ

  • https://www.researchgate.net/profile/Dr_S_Zafar

  • Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity O Yagensky, M Kohansal-Nodehi, S Gunaseelan, T Rabe, S Zafar, I Zerr, ...eLife 8, 2019

  • Cadmium induces GAPDH- and- MDH mediated delayed cell aging and dysfunction in Candida tropicalis 3Aer Z Khan, MA Nisar, S Muzammil, S Zafar, I Zerr, A Rehman Environmental monitoring and assessment 191 (8), 490, 2019

  • The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers K Thüne, M Schmitz, A Villar-Piqué, HC Altmeppen, M Schlomm, S Zafar, ...Expert review of molecular diagnostics 19 (11), 1007-1018, 2019

  • Aberrations of Amyloid-beta in slow and rapidly progressive dementias A Noor, S Zafar, H Dihazi, I Zerr PRION 13, 126-126, 2019

  • Stress granules" road to ruin''in neurodegenerative diseases N Younas, S Zafar, I Zerr PRION 13, 43-44, 2019

  • Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy M Schmitz, A Villar-Piqué, F Llorens, K Gmitterová, P Hermann, D Varges, ...Molecular neurobiology 56 (5), 3476-3483, 2019

  • Seeding variability of different alpha synuclein strains in synucleinopathiesN Candelise, M Schmitz, F Llorens, A Villar‐Piqué, M Cramm, T Thom, ...Annals of neurology 85 (5), 691-703, 2019

  • Prion Protein Strain Diversity and Disease PathologyS Zafar, N Younas, M Shafiq, I Zerr Prions-Some Physiological and Pathophysiological Aspects, 2018

  • DECIPHERING THE PROGRESSION OF ALZHEIMER’S DISEASE BY PROTEOMIC ANALYSIS O Yagensky, MK Nodehi, T Rabe, S Zafar, I Zerr, JJE Chua Alzheimer's & Dementia: The Journal of the Alzheimer's Association 14 (7), P746, 2018

  • Cytoskeleton-associated risk modifiers involved in early and rapid progression of sporadic creutzfeldt-jakob disease S Zafar, N Younas, N Sheikh, W Tahir, M Shafiq, M Schmitz, I Ferrer, ...Molecular neurobiology 55 (5), 4009-4029, 2018

  • Validation of α-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease F Llorens, N Kruse, A Karch, M Schmitz, S Zafar, N Gotzmann, T Sun, ...Molecular neurobiology 55 (3), 2249-2257, 2018

  • Animal TSEs and public health: What remains of past lessons? S Zafar, M Shafiq, O Andréoletti, I Zerr PLoS pathogens 14 (2), e1006759, 2018

  • Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis F Llorens, K Thüne, E Martí, E Kanata, D Dafou, D Díaz-Lucena, ...PLoS pathogens 14 (1), e1006802, 2018

  • Cerebrospinal fluid in Creutzfeldt–Jakob disease I Zerr, S Zafar, M Schmitz, F Llorens Handbook of clinical neurology 146, 115-124, 2018

  • Cellular prion protein mediates early apoptotic proteome alternation and phospho-modification in human neuroblastoma cells S Zafar, C Behrens, H Dihazi, M Schmitz, I Zerr, WJ Schulz-Schaeffer, ...Nature, Cell death & disease 8 (1), e2557-e2557, 2018

  • Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress W Tahir, S Zafar, F Llorens, AS Arora, K Thüne, M Schmitz, N Gotzmann, ...Molecular neurobiology 55 (1), 517-537, 2018

  • Altered Ca 2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease F Llorens, K Thüne, B Sikorska, M Schmitz, W Tahir, N Fernández-Borges, ...Zafar S Acta neuropathologica communications 5 (1), 35, 2017

  • Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies N Candelise, M Schmitz, SM Da Silva Correia, AS Arora, A Villar-Piqué, ...Zafar S Expert review of molecular diagnostics 17 (10), 897-904, 2017

  • Molecular basis of Cd+2 stress response in Candida tropicalis Z Khan, A Rehman, MA Nisar, S Zafar, SZ Hussain, I Zerr, I Hussain, ...Applied microbiology and biotechnology 101 (20), 7715-7728, 2017

  • Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases F Llorens, N Kruse, M Schmitz, N Gotzmann, E Golanska, K Thüne, ...S Zafar Alzheimer's & Dementia 13 (6), 710-719, 2017

  • Effect of metformin on adult hippocampal neurogenesis: comparison with donepezil and links to cognition S Ahmed, Z Mahmood, A Javed, SN Hashmi, I Zerr, S Zafar, S Zahid Journal of Molecular Neuroscience 62 (1), 88-98, 2017

  • Biosorption behavior and proteomic analysis of Escherichia coli P4 under cadmium stressZ Khan, A Rehman, MA Nisar, S Zafar, I Zerr Chemosphere 174, 136-147, 2017

  • Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob diseaseF Llorens Torres, K Thüne, B Sikorska, M Schmitz, W Tahir, ...BioMed Central, 2017

  • Dementia with Lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms P Garcia-Esparcia, I López-González, O Grau-Rivera, MF García-Garrido, S Zafar...Frontiers in neurology 8, 89, 2017

  • Subtype Specific CSF Biomarkers in Sporadic Creutzfeldt-Jakob Disease S Zafar, N Younas, I Zerr J Alzheimers Dis Parkinsonism 7 (332), 2161-0460.1000332, 2017

  • Prion protein interactome: Identifying novel targets in slowly and rapidly progressive forms of Alzheimer’s disease S Zafar, M Shafiq, N Younas, M Schmitz, I Ferrer, I Zerr Journal of Alzheimer's Disease 59 (1), 265-275, 2017

  • Strain-specific altered regulatory response of rab7a and tau in creutzfeldt-jakob disease and alzheimer’s disease S Zafar, N Younas, S Correia, M Shafiq, W Tahir, M Schmitz, I Ferrer, ...Molecular neurobiology 54 (1), 697-709, 2017

  • Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients M Schmitz, F Llorens, A Pracht, T Thom, Â Correia, S Zafar, I Ferrer, I Zerr Aging (Albany NY) 8 (11), 2927, 2016

  • The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases M Schmitz, M Cramm, F Llorens, D Müller-Cramm, S Collins, R Atarashi, ...Nature protocols 11 (11), 2233, 2016

  • Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie M Schmitz, M Cramm, F Llorens, N Candelise, D Müller-Cramm, D Varges, ...Scientific reports 6, 28711, 2016

  • Genetic prion diseases I Zerr, M Schmitz, S Zafar, F Llorens PRION 10, S9-S9, 2016

  • Stratification by genetic and demographic characteristics improves diagnostic accuracy of cerebrospinal fluid biomarkers in rapidly progressive dementia A Karch, F Llorens, M Schmitz, AS Arora, S Zafar, P Lange, C Schmidt, ...Journal of Alzheimer's Disease 54 (4), 1385-1393, 2016

  • Prion protein interactome: Identifying novel targets in rapidly progressive Alzheimer's disease M Shafiq, S Zafar, N Younas, M Schmitz, I Ferrer, I Zerr PRION 10, S97-S97, 2016

  • Early response of Cofilin1 pathway in Creutzfeldt Jakob disease N Younas, S Zafar, M Shafiq, W Tahir, M Schmitz, I Ferrer, O Andreoletti, ...PRION 10, S102-S103, 2016

  • Application of capillary immunoelectrophoresis revealed an age‐and gender‐dependent regulated expression of PrPC in liver AS Arora, S Zafar, O Kollmar, F Llorens, W Tahir, S Vanselow, P Kumar, ...Electrophoresis 36 (24), 3026-3033, 2015

  • Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD F Llorens, N Kruse, M Schmitz, M Shafiq, JEG da Cunha, N Gotzman, ...Journal of neurology 262 (10), 2305-2311, 2015

  • Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy M Schmitz, P Hermann, P Oikonomou, K Stoeck, E Ebert, T Poliakova, ...Neurobiology of aging 36 (9), 2597-2606, 2015

  • Cellular prion protein directly interacts with and enhances lactate dehydrogenase expression under hypoxic conditions S Ramljak, M Schmitz, S Zafar, A Wrede, S Schenkel, AR Asif, J Carimalo, ...Experimental neurology 271, 155-167, 2015

  • Subtype and regional regulation of prion biomarkers in sporadic C reutzfeldt–J akob disease F Llorens, S Zafar, B Ansoleaga, M Shafiq, R Blanco, M Carmona, ...Neuropathology and applied neurobiology 41 (5), 631-645, 2015

  • Creutzfeldt-Jakob disease subtype-specific regional and temporal regulation of ADP Ribosylation Factor-1-dependent Rho/MLC pathway at pre-clinical stage S Zafar, M Schmitz, N Younus, W Tahir, M Shafiq, F Llorens, I Ferrer, ...Journal of Molecular Neuroscience 56 (2), 329-348, 2015

  • Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease A Karch, P Hermann, C Ponto, M Schmitz, A Arora, S Zafar, F Llorens, ... Neurobiology of aging 36 (5), 1964-1968, 2015

  • Alpha-Synuclein: A potential Cerebrospinal fluid biomarker for differentiation of CJD from AD M Shafiq, F Llorens, S Zafar, I Zerr PRION 9, S52-S53, 2015

  • Characterization of differential proteome expression of MM1 and VV2 subtypes of sporadic Creutzfeldt-Jakob disease (sCJD) in Cerebellum W Tahir, S Zafar, M Schmitz, F Llorens, AD Arora, N Younas, I Ferrer, ...PRION 9, S18-S19, 2015

  • Characteristic CSF prion seeding efficiency in humans with prion diseases M Cramm, M Schmitz, A Karch, S Zafar, D Varges, E Mitrova, B Schroeder, ...Molecular neurobiology 51 (1), 396-405, 2015

  • Novel Biomarkers and the Diagnosis of Prion Diseases S Zafar, N Younus, I Zerr J Mol Biomarkers Diagn S 8, 2, 2015

  • Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrPC for the cytoskeleton M Schmitz, S Zafar, CJ Silva, I Zerr Prion 8 (6), 381-386, 2014

  • Subtype and regional-specific neuroinflammation in sporadic Creutzfeldt–Jakob disease F Llorens, I López-González, K Thüne, M Carmona, S Zafar, O Andréoletti, ...Frontiers in aging neuroscience 6, 198, 2014

  • Subtype and regional-specific neuroinflammation in sporadic creutzfeldt-jakob disease F Llorens Torres, I López-González, K Thüne, M Carmona Murillo, S Zafar, ...Frontiers Media, 2014

  • Anchorless 23–230 PrPC Interactomics for Elucidation of PrPC Protective Role S Zafar, AR Asif, S Ramljak, W Tahir, M Schmitz, I Zerr Molecular neurobiology 49 (3), 1385-1399, 2014

  • Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic or …M Schmitz, K Lüllmann, S Zafar, E Ebert, M Wohlhage, P Oikonomou, ...Neurobiology of aging 35 (5), 1177-1188, 2014

  • P. 232: Association of prion protein geno-and PrPSc type with PrPC charge isoform profiles in cerebrospinal fluid of humans with sporadic or familial prion diseases M Schmitz, K Lüllmann, S Zafar, I Zerr Prion 8, 2014 Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease F Llorens, S Zafar, B Ansoleaga, M Shafiq, R Blanco, M Carmona, E Gelpi, ...PRION 8, 121-121, 2014

  • P. 202: Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob diseaseF Llorens, S Zafar, B Ansoleaga, M Shafiq, R Blanco, M Carmona, E Gelpí, ...Prion 8, 2014

  • P. 211: CJD subtype specific interactive role of ADP ribosylation factor-1S Zafar, A Asif, A Arora, M Schmitz, F Llorens, I Ferrer, I Zerr Prion 8, 2014

  • P. 215: Detection and quantification of low prion protein levels in the peripheral tissues by capillary electrophoresis A Arora, M Schmitz, S Zafar, I Zerr Prion 8, 2014

  • Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease JY Douet, S Zafar, A Perret-Liaudet, C Lacroux, S Lugan, N Aron, ...Emerging infectious diseases 20 (1), 114, 2014

  • Impact of the cellular prion protein on amyloid-β and 3PO-tau processing M Schmitz, K Wulf, SC Signore, WJ Schulz-Schaeffer, P Kermer, M Bähr, ...Journal of Alzheimer's Disease 38 (3), 551-565, 2014

  • PrP mRNA and protein expression in brain and PrPc in CSF in Creutzfeldt-Jakob disease MM1 and VV2 F Llorens, B Ansoleaga, P Garcia-Esparcia, S Zafar, O Grau-Rivera, ...Prion 7 (5), 383-393, 2013

  • Characterization of truncated forms of cellular prion protein under inflammatory and demyelinating stress condition by proteomic analysis of the spinal cord: HD. 47 W Tahir, S Zafar, S Nesslar, A Arora, M Shafiq, M Schmitz, C Stadelmann, ...Prion 7, 2013

  • Targeted interactomics to characterize anchorless 23-230 form of PrPC: PS. 30 S Zafar, A Asif, S Ramljak, W Tahir, M Schmitz, I Zerr Prion 7 

  • Temporal degradation of prion biomarkers and relative efficacy of different storage tubes: HD. 09 M Shafiq, S Zafar, M Schmitz, N Sheikh, I Zerr Prion 7, 2013

  • Differential proteome analysis of cytoskeleton associated proteins in the liver of PrP knockout mice: HD. 34 A Arora, S Zafar, M Schmitz, I Zerr Prion 7, 2013

  • Analysis of sporadic Creutzfeldt-Jakob disease patients cerebrospinal fluid by real-time quaking-induced conversion: HD. 02 M Cramm, M Schmitz, A Karch, S Zafar, B Schröder, A Raeber, F Kuhn, ...Prion 7, 54-55, 2013

  • Kinases (Protein Kinases) S Zafar, I Zerr Academic Press, 2013

  • Interactive role of Arf1 and Alpha tubulin-1 protein during the intracellular transportation of prPcS Zafar Prion 6, 2012

  • Cellular Prion Protein (PrPC): Identification and Characterization of Novel Interacting Partners S Zafar Niedersächsische Staats-und Universitätsbibliothek Göttingen, 2011

  • Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells S Zafar, N von Ahsen, M Oellerich, I Zerr, WJ Schulz-Schaeffer, ...Journal of proteome research 10 (7), 3123-3135, 2011

  • Human cellular prion protein (PrPC): Distribution and co-localization with early endosome in the neuronal cell line S Zafar, A Asif, V Armstrong, M Oellerich Clinical Chemistry and Laboratory Medicine 47 (9) , 2009

  • One-STrEP-tagged human prion protein expression, purification, localization and identification of interacting proteins in mammalian cell line S Zafar, A Asif, V Armstrong, M Oellerich Clinical Chemistry and Laboratory Medicine 46 (9) , 2008


Conference papers


  • Zafar S, et al., Zerr I.  Risk modifiers tangled in rapid progression of Alzheimer’s disease. Prion 2017, Edinburgh, Scotland, UK.

  • Zafar S, et al., Zerr I. Proteomic Approaches to Identify the Mechanism of rapid progression of Alzheimer's Disease, European Proteomics Association (EuPA) HUPO2017 Dublin, Ireland.

  • Zafar S, et al., Zerr I. Proteomic and Alzheimer's Disease: novel approaches to classify the Mechanism of rapid progression, 4th World Congress on Mass Spectrometry, 2017, London, UK 

  • Zafar S, and Shafiq M, et al., Zerr I. The prion protein interactome: identifying novel targets in rapidly progressive Alzheimer’s disease. Prion 2016, Tokkyo, Japan.

  • Zafar S, et al., Zerr I. CJD : a pre-symptomatic, subtype specific regional and temporal characterization. Prion 2015, Fort Collins, Colorado, USA

  • Shafiq M, Llorens F, Zafar S, Zerr I. Alpha-Synuclein: A potential Cerebrospinal fluid biomarker for differentiation of CJD from AD. Prion 2015, Fort Collins, Colorado, USA

  • Tahir W, Zafar S et al., Zerr I. Characterization of differential proteome expression of MM1 and VV2 subtypes of sporadic Creutzfeldt-Jakob disease (sCJD) in Cerebellum Fort Collins, Colorado, USA.

  • Zafar S, Oellerich M, Schulz-Schaeffer WJ, Zerr I, Asif AR. Interactive role of Arf1 and Alpha tubulin-1 protein during the intracellular transportation of PrPC. Published in Abstract Book of International conference of Prion 2012 Amsterdam, Netherlands, 2012.

  • Singh AA; Zafar S, Zerr I, Gender and PrPC dependent expression pattern of Tau, P-Tau and APP in the liver of PrPC knockout mice. Published in Abstract Book of International conference of Prion 2012 Amsterdam, Netherlands, 2012.

  • Zafar S, Ahsen NV, Oellerich M, Schulz-Schaeffer WJ, Armstrong VW, Asif AR, Human cellular prion protein (PrPC): Human Cellular Prion Protein (PrPC): Identification of Novel Interacting Partners & Characterization in association with endosome and microtubules. 2010.

  • Zafar S, Asif AR., Armstrong VW, Oellerich M, Human cellular prion protein (PrPC): Distribution and co-localization with early endosome in a neuronal cell line, Clinical chemistry and laboratory medicine, 2009; 47(9):A63. 

  • Zafar S, Asif AR., Armstrong VW, Oellerich M, Molecular interaction of human Prion protein and cytoskeleton associated proteins. Published in Abstract Book of International conference of Prion 2009 Thessaloniki-Chalkidiki, Greece, 2009.

  • Zafar S, Asif AR., Armstrong VW, Oellerich M, One-STrEP-tagged human prion protein expression, purification, localization and identification of interacting proteins in mammalian cell line, Clinical chemistry and laboratory medicine, 2008; 46(9):A175.

  • Zafar S, Epidemiological Evaluation and Surveillance Priority meeting 25TH June, 2014, Brussel, 2014 Belgium 

  • Zafar S Human prions – distinguishing sporadic from genetic forms via structure and function    HAI meeting 27TH May, 2014, Trieste, Italy

  • Zafar S Anchorless 23-230 PrPC interactomics 18 TH September, 2013, Göettingen, Germany

  • Zafar S Proteomics and Interactomics – Approaches to Novel Biomarkers DEMTEST 05 TH September, 2013, Göettingen, Germany

  • Zafar S, Characterization of time-dependant evolution of brain and blood proteomes from MM1-and VV2-infected Met129 and Val129 mice 04TH June, 2013, DZNE meeting, Göettingen, Germany 

  • Zafar S ZNE-GBA study: Markers in GBA-associated PD (MIGAP) -early detection, progression, mechanisms, protection 18TH April, 2013, NGFN meeting, Tübingen, Germany

  • Zafar S Proteomics and Interactomics – Approaches to Novel Biomarkers DEMTEST. 25 th August, 2012, JPND meeting, Hannover, Germany

  • Zafar S Biomarker based diagnosis of rapid progressive dementias-optimisation of diagnostic protocols- DEMTEST. 24th August, 2012, JPND meeting, Hannover, Germany. 

  • Zafar S Proteomics to Genomics: Involvement of Peripheral organs In Tauopathies and Prionopathies. 1 st june, 2012, KNDD meeting, Würzburg, Germany

  • Zafar S Interactive role of Arf1 and alpha tubulin-1 with cellular prion protein transportation in neuronal cells. 10th Feb, 2012 National Reference Center for TSEs Surveillance, Goettingen, Germany

  • Zafar S Protecting the food chain from prions: shaping European priorities through basic and applied research. 15TH September, 2011, Priority International Conference/Consortium, National Reference Center for TSEs Surveillance, Goettingen, Germany.

  • Zafar S Proteomics Approach to Identify the Interacting Partners of Cellular Prion Protein and Characterization of Rab7a Interaction in Neuronal Cells. 12TH August, 2011, National Reference Center for TSEs Surveillance, Goettingen, Germany

  • Zafar S Intracellular transportation of PrPC : interactive role of Arf1 and Alpha tubulin-1 proteins. 10TH February, 2012, National Reference Center for TSEs Surveillance, Goettingen, Germany.

  • Zafar S Characterization of time-dependant evolution of brain and blood proteome alterations induced by various sCJD strains. 15TH September, 2011, Priority International Conference, National Reference Center for TSEs Surveillance, Goettingen, Germany. 

  • Zafar S Proteomics Approach to Identify the Interacting Partners of Cellular Prion Protein and Characterization of Rab7a Interaction in Neuronal Cells. 12TH August, 2011, National Reference Center for TSEs Surveillance, Goettingen, Germany.

  • Zafar S Human cellular prion protein (PrPC ): Human Cellular Prion Protein (PrPC):Identification of Novel Interacting Partners & Characterization in association with endosome and microtubules. 17st October, 2010, Goettinger Transporttage. Conference Goettingen, Germany.

  • Zafar S Cellular Prion protein (PrPC ): Localization & Identification of Interacting Proteins using STrEPTM technology and proteomics. 4 -5 th June, 2009, 6th Meeting (Prion screen project- Development of a blood screening assay for diagnosis of prion, diseases in humans), Berlin, Germany.

  • Zafar S Human cellular prion protein (PrPC): Distribution and colocalization with early endosome in a neuronal cell line”. 5th. Jahrestagung der DGKL Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin, Mannheim, Germany.

  • Zafar S Molecular interaction of human Prion protein and cytoskeleton associated proteins”. The international conference "Prion 2009" Chalkidiki, Greece. 

  • Zafar S Cellular Prion protein (PrPC): Localization & Identification of Interacting Proteins using STrEPTM technology and proteomics. 21st September, 2009, 5th Meeting (Prion screen project- Development of a blood screening assay for diagnosis of prion, diseases in humans), Thessaloniki, Greece.

  • Zafar S Cellular Prion protein (PrPC): Localization & Identification of Interacting Proteins using STrEPTM technology and proteomics.2009, 3rd Meeting (Prion screen project-), Göttingen, Germany.

  • Zafar S Comparative analysis, cellular localization & functional characterization of proteins interacting with normal and variant prion proteins. 25th March, 2009, University Medical Centre of Göttingen, Göttingen, Germany

  • Zafar S Cellular Prion protein (PrPC ): Expression, Purification, Localization & Identification of Interacting Proteins18th February, 2009, Department of Clinical Chemistry Georg-August-University, University Medical Centre of Göttingen, Göttingen, Germany.

  • Zafar S Identification of potential biomarker of CJD using STrEP technology and proteomics-an introduction. 28th January, 2009, Clinical Chemistry Georg-August-University, Göttingen, Germany.

  • Zafar S One-STrEP-tagged human prion protein expression, purification, localization and identification of interacting proteins in mammalian cell line”. 20086 th.Jahrestagung der DGKL Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin, Leipzig, Germany.

  • Zafar S One-STrEP-tagged human Prion protein expression, purification, and localization in mammalian cell line, 29th August, 2008, 3rd Meeting (Prion screen project Development of a blood screening assay for diagnosis of prion, diseases in humans), 2008 Bratislava, Slovakia.

  • Zafar S Cloning of Human Prion protein with One Strep TM-tag, site directed Mutagenesis and Expression analysis in HEK293 and HpL3-4 cell lines. 14th January, 2008, 2nd Meeting (Prion screen project- Development of a blood screening assay for diagnosis of prion diseases in humans), Krakow, Poland.

  • Zafar S Comparative analysis, Cellular localization & Functional characterization of proteins interacting with Normal and Variant Prion Protein. 17th June, 2007, Clinical Chemistry Georg-August-University, Göttingen, Germany.

  • Lahore Bio-Forum 2006, The Twin Center for Molecular Biology, CEMB, University of the Punjab, Lahore – Pakistan. 2006

 Teaching Faculty Molecular Medicine Program | George August University, Medical Center, Gottingen, Germany | Jan. 2015- 2019

  • Subjects Masters Level
  • Neurology

Teaching Faculty Biomedical Engineering and Sciences Department, School of Mechanical and Manufacturing Engineering (SMME), | National University of Sciences and Technology (NUST), Islamabad, Pakistan | Jan. 2019- Present

Subjects Masters Level

  • Molecular neuroscience

  • Cancer cytogenetics

  • Human Physiology & Anatomy

  • System Pharmacology & Therapeutic​